CANTON, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will
present data on Xtampza® ER, an extended-release oral formulation of oxycodone with abuse-deterrent properties, at PAINWeek 2017 on
September 7th in Las Vegas.
The following posters will be presented during the poster session on Thursday, September 7th from 6:30 pm - 8:30 pm PT:
- Poster #18, titled “Converting patients with chronic pain from immediate-release oxycodone to Xtampza ER, an
extended-release, abuse-deterrent formulation” is a post hoc analysis of data from patients with chronic low back pain previously
uncontrolled with immediate-release oxycodone, who were converted to Xtampza ER as part of a Phase 3 randomized withdrawal,
double-blind, placebo-controlled, enriched-enrollment, parallel-group, multicenter, 12-week clinical study
- Poster #19, titled “Assessment of the oral human abuse liability and pharmacokinetics of Xtampza ER,” presents results from a
study evaluating the abuse potential and pharmacokinetics of oral administration of Xtampza ER compared to chewed Xtampza ER, and
crushed immediate-release oxycodone in solution in non-dependent, recreational drug abusers.
- Poster #100, titled “Reality and Responsibility Revisited: Stakeholder Accountability in the Effort to Develop Safer Opioids”
describes the scientific and clinical issues surrounding the development of Abuse Deterrent Opioids. The commentary delineates
how multiple stakeholders have a role to play in the effort to improve opioid safety overall and specifically in the development
of safer opioid products.
For more information on PAINWeek 2017, visit http://www.painweek.org/.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary
DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is
designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent,
extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
LIMITATIONS OF USE
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks
of overdose and death with extended-release opioid formulations, reserve Xtampza ER for use in patients for whom alternative
treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise
inadequate to provide sufficient management of pain.
Xtampza ER is not indicated as an as-needed (prn) analgesic.
The Full Prescribing Information for Xtampza ER contains the following Boxed Warning:
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL
OPIOID WITHDRAWAL SYNDROME; and CYTOCHROME P450 3A4 INTERACTION
Addiction, Abuse, and Misuse
Xtampza ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and
death. Assess each patient’s risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of
these behaviors or conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of Xtampza ER. Monitor for respiratory
depression, especially during initiation of Xtampza ER or following a dose increase.
Accidental Ingestion
Accidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of oxycodone.
Neonatal Opioid Withdrawal Syndrome
Prolonged use of Xtampza ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life threatening if
not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is
required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and
ensure that appropriate treatment will be available.
Cytochrome P450 3A4 Interaction
The concomitant use of Xtampza ER with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma
concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In
addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma
concentration. Monitor patients receiving Xtampza ER and any CYP3A4 inhibitor or inducer.
IMPORTANT SAFETY INFORMATION
Xtampza ER is contraindicated in patients with: significant respiratory depression; acute or severe bronchial asthma in an
unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including
paralytic ileus; and hypersensitivity (e.g., anaphylaxis) to oxycodone.
Xtampza ER contains oxycodone, a Schedule II controlled substance. As an opioid, Xtampza ER exposes users to the risks of
addiction, abuse, and misuse. As extended-release products, such as Xtampza ER, deliver the opioid over an extended period of time,
there is a greater risk for overdose and death due to the larger amount of oxycodone present.
Potential serious adverse events caused by opioids include addiction, abuse, and misuse, life-threatening respiratory
depression, neonatal opioid withdrawal syndrome, risks of concomitant use or discontinuation of cytochrome P450 3A4 inhibitors and
inducers, risks due to interactions with central nervous system depressants, risk of life-threatening respiratory depression in
patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients, adrenal insufficiency, severe
hypotension, risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness,
risks of use in patients with gastrointestinal conditions, risk of use in patients with seizure disorders, withdrawal, risks of
driving and operating machinery, and laboratory monitoring.
The most common AEs (>5%) reported by patients in the Phase 3 clinical trial during the titration phase were: nausea
(16.6%), headache (13.9%), constipation (13.0%), somnolence (8.8%), pruritus (7.4%), vomiting (6.4%), and dizziness (5.7%).
For Important Safety Information including full prescribing information visit: http://www.xtampzaer.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's
expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties
relating to a number of other factors, including the following: our ability to obtain and maintain regulatory approval of our
products and product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product;
our plans to commercialize our product candidates and grow sales of our products; the size and growth potential of the markets for
our products and product candidates, and our ability to service those markets; the success of competing products that are or become
available; our ability to obtain reimbursement and third-party payor contracts for our products; the costs of commercialization
activities, including marketing, sales and distribution; our ability to develop sales and marketing capabilities, whether alone or
with potential future collaborators; the rate and degree of market acceptance of our products and product candidates; changing
market conditions for our products and product candidates; the outcome of any patent infringement or other litigation that may be
brought against us, including litigation with Purdue Pharma, L.P.; our ability to attract collaborators with development,
regulatory and commercialization expertise; the success, cost and timing of our product development activities, studies and
clinical trials; our ability to obtain funding for our operations; regulatory developments in the United States and foreign
countries; our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for
our products and product candidates; our ability to operate our business without infringing the intellectual property rights of
others; the performance of our third-party suppliers and manufacturers; our ability to comply with stringent U.S. and foreign
government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance; our ability
to retain key and management personnel; our expectations regarding the period during which we qualify as an emerging growth company
under the JOBS Act; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional
financing. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the
year ended December 31, 2016, and those risks described from time to time in other reports which we file with the SEC. Any
forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no
obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the
date of this press release.
Contact: Alex Dasalla [email protected]
